



GLAND PHARMA LIMITED

June 04, 2025

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Update on the ANSM Inspection at Cenexi's Fontenay Manufacturing Facility

In continuation to our intimation dated December 25, 2024; this is to inform you that the Agence nationale de sécurité du médicament et des produits de santé (ANSM), France, has issued its final report citing 11 (Eleven) observations, in pursuance of the Good Manufacturing Practices (GMP) inspection of Cenexi's Fontenay Manufacturing Facility ('Facility') (material subsidiary of Gland Pharma Limited) between 9th December to 19th December, 2024.

Cenexi has undertaken a Corrective and Preventive Action Plan, with various appropriate measures, within a period ranging from 3 -12 months (varies for each observation), and the same has been accepted by ANSM. There will be no disruption in the manufacturing operations due to this final inspection report.

Cenexi is committed to working closely with the ANSM to address the Observations and will provide further updates to the Exchanges as they become available.

The information required as per Regulation 30 read with Schedule III Para A Sub Para 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as **Annexure A**.

Please take the above information on record.

**Yours truly,
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer**

**Annexure A**

Sl. No	Particulars	Remarks
1	Name of the authority	Agence nationale de sécurité du médicament et des produits de santé (ANSM), France
2	Nature and details of the action(s) taken or order(s) passed;	Final report with 11 (Eleven) observations
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	June 03, 2025
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	Not Applicable
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There will be no disruption in the manufacturing operations.